Prajapati Vimal H, Bellefontaine Nicole, Gopalan Devi, Mangaser Rommel, Chan Pak, Sauder Maxwell B
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Meadows Mile Professional Building, Calgary, AB, T2J 7E1, Canada.
Dermatol Ther (Heidelb). 2025 May 29. doi: 10.1007/s13555-025-01434-x.
Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved in several countries to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Limited data are available on tildrakizumab treatment patterns in clinical practice. The Canadian tildrakizumab patient support program (PSP), which provides personalized reimbursement, financial aid, and injection training support for disease management, was used in this study to evaluate real-world persistence and adherence to tildrakizumab.
This retrospective, observational study used data collected in the Canadian tildrakizumab PSP database between August 4, 2021, and August 1, 2023. Adult (≥18 years) patients with moderate-to-severe plaque psoriasis who enrolled in the PSP and received ≥6 months of treatment with tildrakizumab before August 1, 2023, were included. Data up to Week 52 following treatment initiation were analyzed. Persistence was defined as the number of days until treatment discontinuation. Adherence was measured as the proportion of days covered (PDC) from treatment initiation to treatment discontinuation or study cutoff, with PDC ≥80% indicating high adherence.
The study included 813 patients with a mean ± standard deviation (SD) age of 49.6 ± 15.9 years; 55.0% (447/813) were male, and 92.7% (754/813) were biologic-naïve when initiating tildrakizumab. Patients received tildrakizumab treatment for a mean ± SD of 329.6 ± 55.0 days. After 1 year, 88.0% of patients were persistent on treatment. Adherence was also high, with mean ± SD PDC being 97.5% ± 8.9% and 93.5% of patients having PDC ≥80%. Eighty-five patients discontinued treatment, primarily because of switching to other therapies. Common adverse outcomes included treatment misuse (18.9%), disease flare (8.2%), and treatment discontinuation (7.4%).
Persistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP.
替拉珠单抗是一种抗白细胞介素-23 p19单克隆抗体，已在多个国家获批用于治疗适合光疗或全身治疗的中度至重度斑块状银屑病成年患者。关于替拉珠单抗在临床实践中的治疗模式的数据有限。本研究使用了加拿大替拉珠单抗患者支持项目（PSP），该项目为疾病管理提供个性化报销、经济援助和注射培训支持，以评估替拉珠单抗在现实世界中的持续用药情况和依从性。
这项回顾性观察研究使用了2021年8月4日至2023年8月1日期间在加拿大替拉珠单抗PSP数据库中收集的数据。纳入了年龄≥18岁、患有中度至重度斑块状银屑病且在2023年8月1日前参加PSP并接受替拉珠单抗治疗≥6个月的成年患者。分析了治疗开始后至第52周的数据。持续用药定义为直至治疗中断的天数。依从性通过从治疗开始至治疗中断或研究截止期间的覆盖天数比例（PDC）来衡量，PDC≥80%表示高依从性。
该研究纳入了813例患者，平均年龄为49.6±15.9岁（均值±标准差）；55.0%（447/813）为男性，92.7%（754/813）在开始使用替拉珠单抗时未使用过生物制剂。患者接受替拉珠单抗治疗的平均天数为329.6±55.0天。1年后，88.0%的患者持续接受治疗。依从性也很高，平均PDC为97.5%±8.9%，93.5%的患者PDC≥80%。85例患者停止治疗，主要原因是改用其他疗法。常见的不良结局包括治疗不当（18.9%）、疾病复发（8.2%）和治疗中断（7.4%）。
在参加加拿大PSP的中度至重度斑块状银屑病患者中，替拉珠单抗治疗52周期间的持续用药情况和依从性较高。
